Compare Plug Power Inc (PLUG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plug Power Inc vs Recursion Pharmaceuticals Inc — how do they compare? Plug Power Inc trades at $1.75 (market cap $2.49B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.31B). The key difference: Plug Power Inc and Recursion Pharmaceuticals Inc are close in size by market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Plug Power Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Plug Power Inc for 41 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| PLUG | RXRX | |
|---|---|---|
Market Cap | $2.49B | $2.31B |
Volume | 47,846,349 | 40,478,768 |
Sector | Industrials | Health |
52-Week High | $4.14 | $6.79 |
52-Week Low | $1.73 | $2.84 |
Typical Hold Time | 41 Days | 22 Days |
Enterprise Value | $3.36B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Plug Power (PLUG) trades at $1.78, down 4.3% today, with a bearish technical outlook and negative earnings momentum. The company continues to report significant losses with a net income margin of -220.59% and negative cash flow, though recent news highlights strategic partnerships including a 280 MW electrolyzer agreement with Arcadia eFuels. Analyst consensus shows mixed sentiment with 44.7% buy ratings and a $3.13 price target, representing 76% upside potential from current levels.
While PLUG shows potential through hydrogen infrastructure expansion and recent contract wins, the investment case remains high-risk due to persistent negative profitability, cash burn, and competitive pressures. The stock trades near analyst low targets, suggesting limited downside protection, making it suitable only for speculative investors comfortable with substantial volatility and execution risk in the clean energy sector.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Plug Power Inc
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
